BioSpace News Archive

Captor Therapeutics S.A. announces the molecular targets of one of its core pipeline projects designated CT-01, which is focused on the development of TPD therapy for hepatocellular carcinoma.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that CEO Nawal Ouzren will attend in person two investor meetings in April 2022.

PureTech Health plc announced the publication of preclinical proof-of-concept demonstrating that PureTech’s Glyph platform can enhance the oral bioavailability of buprenorphine, a clinically-validated opioid replacement therapy, further expanding the range of clinically-validated drug classes shown to be amenable to the Glyph technology.

ReiThera Srl and Exothera announced that they have entered into a collaboration agreement to develop a large-scale, low cost per dose manufacturing process for the production of ReiThera’s novel vaccines.

Keymed Biosciences announced that its new drug candidate CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by the Food and Drug Administration of the United States recently.

The Annual General Meeting of Promore Pharma AB will be held on Tuesday, 17 May 2022 at 2 pm, in the premises of Wennergren Center, Biblioteket, floor 24, Sveavägen 166, in Stockholm.

Devyser announces a strengthening of its commercial organization with the appointment of Theis Kipling as Chief Commercial Officer with global responsibility for sales, marketing, product management and tech support.

DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, announced the launch of a new program for customers of their SYNTAX System, in which organizations receive early access to the latest advancements of their EDS technology.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced that Igor Smolenov, Senior Vice President, Global Clinical Development, will deliver a presentation at the World Vaccine Congress Washington 2022.

ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF PHASE I CLINICAL TRIAL OF AT2 78 ULTRA-CONCENTRATED ULTRA- RAPID ACTING INSULIN FOR DIABETES.